Philip L Molyneaux

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7804162/publications.pdf

Version: 2024-02-01

85	6,531	101384	71532
papers	citations	36 h-index	76 g-index

95	95	95	7598
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nature Genetics, 2013, 45, 613-620.	9.4	667
2	Outgrowth of the Bacterial Airway Microbiome after Rhinovirus Exacerbation of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1224-1231.	2.5	329
3	Persistent Postâ€“COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Annals of the American Thoracic Society, 2021, 18, 799-806.	1.5	306
4	Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respiratory Medicine,the, 2015, 3, 462-472.	5.2	252
5	Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respiratory Medicine,the, 2017, 5, 869-880.	5.2	233
6	PD-1 up-regulation on CD4 ⁺ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-Î²1 production. Science Translational Medicine, 2018, 10, .	5.8	225
7	Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 564-574.	2.5	208
8	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respiratory Medicine,the, 2020, 8, 925-934.	5.2	198
9	The microbiome in respiratory medicine: current challenges and future perspectives. European Respiratory Journal, 2017, 49, 1602086.	3.1	194
10	Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax, 2013, 68, 436-441.	2.7	193
11	An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respiratory Medicine,the, 2017, 5, 946-955.	5.2	190
12	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1656-1665.	2.5	171
13	Hostâ€“Microbial Interactions in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1640-1650.	2.5	169
14	Utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with tuberculous intrathoracic lymphadenopathy: a multicentre study. Thorax, 2011, 66, 889-893.	2.7	166
15	Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respiratory Research, 2017, 18, 29.	1.4	156
16	The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. European Respiratory Review, 2013, 22, 376-381.	3.0	148
17	Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 759-770.	5.2	145
18	Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 989-997.	2.5	138

#	Article	IF	Citations
19	Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respiratory Medicine,the, 2017, 5, 857-868.	5.2	115
20	Dynamics of human monocytes and airway macrophages during healthy aging and after transplant. Journal of Experimental Medicine, 2020, 217, .	4.2	113
21	Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 74-81.	2.5	107
22	Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2021, 57, 2002559.	3.1	106
23	Respiratory microbiome and epithelial interactions shape immunity in the lungs. Immunology, 2020, 160, 171-182.	2.0	103
24	Lung microbiology and exacerbations in COPD. International Journal of COPD, 2012, 7, 555.	0.9	101
25	A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1801992.	3.1	101
26	Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity, 2022, 55, 542-556.e5.	6.6	96
27	Methods in Lung Microbiome Research. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 283-299.	1.4	94
28	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	2.5	90
29	The Transferrin Receptor CD71 Delineates Functionally Distinct Airway Macrophage Subsets during Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 209-219.	2.5	82
30	Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort. Respiratory Research, 2019, 20, 148.	1.4	77
31	Itaconate controls the severity of pulmonary fibrosis. Science Immunology, 2020, 5, .	5.6	73
32	Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2018, 142, 815-823.e6.	1.5	63
33	The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget, 2017, 8, 48737-48754.	0.8	48
34	The respiratory microbiome in idiopathic pulmonary fibrosis. Annals of Translational Medicine, 2017, 5, 250-250.	0.7	48
35	The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 339-347.	2.5	45
36	A Comparison between Two Strategies for Monitoring Hepatic Function during Antituberculous Therapy. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 653-659.	2.5	44

#	Article	IF	Citations
37	Enhanced IL-1Î² Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis. Frontiers in Immunology, 2021, 12, 661811.	2.2	43
38	Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent. European Respiratory Journal, 2020, 55, 1901519.	3.1	42
39	Microbiome in interstitial lung disease. Current Opinion in Pulmonary Medicine, 2017, 23, 404-410.	1.2	41
40	The Role of the Lungâ€™s Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2019, 20, 5618.	1.8	41
41	A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled Î±vÎ²6 integrin inhibitor. Respiratory Research, 2020, 21, 75.	1.4	41
42	Lung function trajectory in progressive fibrosing interstitial lung disease. European Respiratory Journal, 2022, 59, 2101396.	3.1	40
43	The burden of progressive fibrotic interstitial lung disease across the UK. European Respiratory Journal, 2021, 58, 2100221.	3.1	39
44	The contribution of infection and theÂrespiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis. European Respiratory Review, 2019, 28, 190045.	3.0	37
45	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.4	33
46	The potential impact of azithromycin in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1800628.	3.1	32
47	Right Ventricular to Left Ventricular Ratio atÂCT Pulmonary Angiogram Predicts Mortality in Interstitial Lung Disease. Chest, 2020, 157, 89-98.	0.4	30
48	Serum markers of pulmonary epithelial damage in systemic sclerosisâ€associated interstitial lung disease and disease progression. Respirology, 2021, 26, 461-468.	1.3	30
49	Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-Î± antagonist therapy. Thorax, 2013, 68, 955-961.	2.7	29
50	Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis. Communications Biology, 2021, 4, 392.	2.0	28
51	Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 197-208.	2.5	27
52	Airway mucins promote immunopathology in virus-exacerbated chronic obstructive pulmonary disease. Journal of Clinical Investigation, 2022, 132, .	3.9	27
53	Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting. American Journal of Surgical Pathology, 2020, 44, 347-356.	2.1	25
54	Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 56-69.	2.5	25

#	Article	IF	Citations
55	Respiratory microbiome in IPF: cause, effect, or biomarker?. Lancet Respiratory Medicine,the, 2014, 2, 511-513.	5.2	24
56	Early prognostication of COVID-19 to guide hospitalisation versus outpatient monitoring using a point-of-test risk prediction score. Thorax, 2021, 76, 696-703.	2.7	24
57	In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia isÂassociated with disease progression andÂmortality. European Respiratory Journal, 2019, 53, 1802412.	3.1	20
58	50-gene risk profiles in peripheral blood predict COVID-19 outcomes: A retrospective, multicenter cohort study. EBioMedicine, 2021, 69, 103439.	2.7	20
59	Clinical Genetics in Interstitial Lung Disease. Frontiers in Medicine, 2018, 5, 116.	1.2	19
60	Time for an International Consensus on Hypersensitivity Pneumonitis. A Call to Arms. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 665-666.	2.5	18
61	Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Design, Development and Therapy, 2013, 7, 503.	2.0	17
62	Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European Populations. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 775-778.	2.5	17
63	DNA Methylome Alterations Are Associated with Airway Macrophage Differentiation and Phenotype during Lung Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 954-966.	2.5	17
64	Wearable In-Ear PPG: Detailed Respiratory Variations Enable Classification of COPD. IEEE Transactions on Biomedical Engineering, 2022, 69, 2390-2400.	2.5	17
65	BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 136-139.	2.5	15
66	Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases. International Journal of Molecular Sciences, 2022, 23, 977.	1.8	14
67	Defining genetic risk factors for scleroderma-associated interstitial lung disease. Clinical Rheumatology, 2020, 39, 1173-1179.	1.0	12
68	Candidate Role for Toll-like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 550-562.	2.5	12
69	Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease. European Respiratory Journal, 2020, 55, 1901681.	3.1	11
70	Interstitial lung disease incidence and mortality in the UK and the European Union: an observational study, 2001â€“2017. ERJ Open Research, 2022, 8, 00058-2022.	1.1	11
71	Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2â€tier nuclear grade. Histopathology, 2020, 77, 423-436.	1.6	9
72	Interaction between the promoter MUC5B polymorphism and mucin expression: is there a difference according to ILD subtype?. Thorax, 2020, 75, 901-903.	2.7	8

#	Article	IF	Citations
73	Regularized Latent Class Model for Joint Analysis of High-Dimensional Longitudinal Biomarkers and a Time-to-Event Outcome. Biometrics, 2019, 75, 69-77.	0.8	7
74	The Challenging Road of Moving from Association to Causation for Microbiome Research in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1054-1056.	2.5	6
75	PAciFy Coughâ€"a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough. Trials, 2022, 23, 184.	0.7	6
76	Evaluation of a re-useable bronchoscopy biosimulator with ventilated lungs. ERJ Open Research, 2019, 5, 00035-2019.	1.1	5
77	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. Advances in Therapy, 2019, 36, 3059-3070.	1.3	4
78	Rapidly Progressive Cystic Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 264-264.	2.5	2
79	The microbiome in IPF: tissue is not the issue. Thorax, 2021, 76, 218-218.	2.7	1
80	Interstitial lung disease. , 2019, , 173-187.		1
81	Autoantibodies are present in the bronchoalveolar lavage but not circulation in patients with fibrotic interstitial lung disease. ERJ Open Research, 2022, 8, 00481-2021.	1.1	1
82	Choosing pharmacotherapy for ILD in patients with connective tissue disease. Breathe, 2021, 17, 210114.	0.6	1
83	Could quality be the key in connective tissue diseaseâ€associated interstitial lung disease?. Respirology, 2018, 23, 801-802.	1.3	0
84	Review of the British Thoracic Society Winter Meeting 2017, 6â€"8 December 2017, London, UK. Thorax, 2018, 73, 872-876.	2.7	0
85	The Respiratory Microbiome in Health and Disease. , 2022, , 177-184.		0